Drug Interaction Report
2 potential interactions and/or warnings found for the following 2 drugs:
- cobimetinib
- Culturelle HS (lactobacillus rhamnosus gg)
Interactions between your drugs
lactobacillus rhamnosus GG cobimetinib
Applies to: Culturelle HS (lactobacillus rhamnosus gg), cobimetinib
If you are currently being treated or have recently been treated with cobimetinib, you should let your doctor know before using lactobacillus rhamnosus GG. Depending on the dose and length of time you have been on cobimetinib, you may be at risk for developing rare infections from exposure to products containing live bacteria or yeast. Depending on your overall health and medical condition, it may be advisable to avoid using lactobacillus rhamnosus GG until your immune system has recovered from the effects of cobimetinib. Talk to your doctor if you have any questions or concerns. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Drug and food interactions
cobimetinib food
Applies to: cobimetinib
Grapefruit juice may increase the blood levels and effects of certain medications such as cobimetinib. You may want to limit your consumption of grapefruit and grapefruit juice during treatment with cobimetinib. However, if you have been regularly consuming grapefruit or grapefruit juice with cobimetinib, do not alter the amounts of these products in your diet without first talking to your doctor or other healthcare professional. Contact your doctor if your condition changes or you experience increased side effects. Orange juice is not expected to interact.
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
See also:
Keytruda
Keytruda is used to treat multiple types of cancer such as melanoma, non-small cell lung cancer ...
Opdivo
Opdivo is used to treat many cancers, such as melanoma, non-small cell lung cancer, malignant ...
Ozempic
Learn about Ozempic (semaglutide) for type 2 diabetes treatment, weight management, cardiovascular ...
Yervoy
Yervoy (ipilimumab) is a cancer treatment used for lung cancer, melanoma, renal cell carcinoma ...
Mekinist
Mekinist is used to treat melanoma, non-small cell lung cancer, thyroid cancer, solid tumors, and ...
Braftovi
Braftovi is a targeted cancer treatment used in combination with Mektovi, mFOLFOX6, or Erbitux, to ...
Tafinlar
Tafinlar is a prescription medicine used to treat BRAF mutated melanoma, non-small cell lung ...
Mektovi
Mektovi (binimetinib) is an oral kinase inhibitor that may be used in combination with encorafenib ...
Zelboraf
Zelboraf (vemurafenib) is used to treat skin cancer (metastatic melanoma). Includes Zelboraf side ...
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.